ReviewMinerva endocrinologica2012
Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions.
Review in Minerva endocrinologica, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Sorafenib and radioiodine-refractory differentiated thyroid cancer (RR-DTC): a systematic review and meta-analysis.Endocrine · 2020Pooled it
- Somatostatin receptor expression for peptide receptor radionuclide therapy in Japanese patients with recurrent or metastatic differentiated thyroid cancer.Annals of nuclear medicine · 2026Article
- Visual and QuantitativeMolecular imaging and biology · 2025Article
- Impact of systemic treatments for advanced thyroid cancer on the adrenal cortex.European thyroid journal · 2024Article
- Management of hypertension during lenvatinib for advanced thyroid cancer: a suggested diagnostic and therapeutic algorithm.European thyroid journal · 2023Article
- Article
- Review
- Multikinase inhibitors in thyroid cancer: timing of targeted therapy.Nature reviews. Endocrinology · 2021Review
- Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Actions of Thyroid Hormones on Thyroid Cancers.Frontiers in endocrinology · 2021Review
- Akt1 genetic variants confer increased susceptibility to thyroid cancer.Endocrine connections · 2020Article
- Treatment and prognosis for patients with differentiated thyroid carcinoma bone metastases.Translational cancer research · 2020Article
- Successful Treatment by Surgery and Lenvatinib of a Patient with Adrenal Metastasis of Papillary Thyroid Cancer.Case reports in oncological medicine · 2020Article
- Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine-refractory differentiated thyroid carcinomas.Cancer medicine · 2018Article
- Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.The Journal of clinical endocrinology and metabolism · 2018Article
- Observational
- Timing of multikinase inhibitor initiation in differentiated thyroid cancer.Endocrine-related cancer · 2017Observational
- PDGFRα Regulates Follicular Cell Differentiation Driving Treatment Resistance and Disease Recurrence in Papillary Thyroid Cancer.EBioMedicine · 2016Article
- Management of Invasive Differentiated Thyroid Cancer.Thyroid : official journal of the American Thyroid Association · 2016Review
- Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer.Cancer management and research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The majority of patients with differentiated thyroid cancer are cured with standard primary treatments including surgery, radioactive iodine and TSH suppression. A small proportion of patients who develop radioactive iodine-refractory metastatic disease have few treatment options. Recent discovery of the molecular mechanisms that contribute to thyroid cancer tumorigenesis and its progression have revealed key targets that are currently being evaluated in clinical trials. In the last decade several novel targeted therapies have shown encouraging results and have brought hope to patients with advanced disease. However, identifying the subpopulation of patients who may benefit from systemic therapies remains a challenge as the use of these therapeutic modalities is associated with high toxicity rates and most patients have a long indolent phase where the tumor is stable or slowly progressive and asymptomatic. The objective of this review is to summarize the management of patients with metastatic, radioactive iodine refractory differentiated thyroid cancer.
Indexed as
Identifiers
23235190PMC3980664W939443852What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.